• Health
  • Science
  • U.S.
  • Technology
  • Business
  • World
  • Politics
  • Entertainment
  • Sports

Building a Better World

News and information

  • Home
  • Privacy Policy
  • Contact Us
  • Our Team

Northwest Biotherapeutics aims to break new ground in battle against cancer with new product

March 10, 2014 By Contributor

Northwest Biotherapeutics aims to break new ground in battle against cancer with new product

Northwest Biotherapeutics continues work to battle cancer.

The small Maryland-based company, Northwest Biotherapeutics, nearly closed 10 years ago after it almost ran out of cash. With just one week to go before its doors closed, the company was saved by financial backer Linda Powers. Now, the company hopes to assert itself in a field that has seen well-known failures by developing experimental treatments and therapies for brain cancer and various inoperable tumors.

Powers became chairman of the company in 2007 and has invested over $20 million in the company and its drugs. Northwest is now worth almost $300 million, and has seen a jump in stocks up to the $7 range just this year. However, despite attention from institutional investors such as Goldman Sachs and Franklin Advisers Inc., some investors are wary of the company, noting the uncertainty and high risks involved with developing drugs for diseases that are difficult to treat.

Powers asserts in a recent Reuters interview, “Biotech is not for the faint of heart.” She continues, “Through two major recessions and pummeling in the capital markets, we’ve chosen to keep our focus.”

The hallmark of the company is a brain cancer drug called DCVax-L. This drug has been paramount to the company’s survival, providing strong trial results in a small selection of patients. Northwest has recently begun to test a similar drug called DCVax-Direct, which is designed for use against many different types of tumors that cannot be removed through surgery. These tumors are associated with cancers such as colon, pancreatic, breast and melanoma.

This drug is one of a new trend of similar drugs that prompts the body’s immune system to find and kill cancer cells with dendritic cells, which call upon t-cells and b-sells to make antibodies against the disease.

Biotech analyst for Summer Street Research, Carol Werther, said, “If (DCVax-L) has a positive result, it could be the new standard for care of brain cancer and have potential for hundreds of millions of dollars in sales for newly diagnosed patients.” She adds, “And if it works against other solid tumors, it could be a multibillion-dollar product.”

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Filed Under: Front Page, Health, None, U.S.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebookrss

Search:

Recent Posts

  • NASA’s InSight spacecraft makes important course correction May 26, 2018
  • Scientists outraged at latest Trump decision May 15, 2018
  • Huge uproar erupts over major incident at Utah park May 13, 2018
  • Incredible moon discovery stuns scientists May 12, 2018
  • Authorities shocked by discovery about common painkiller May 6, 2018
  • Outrageous crocodile experiment stuns scientists May 5, 2018
  • Great Barrier Reef is too quiet, scientists say May 1, 2018
  • Massive Hiroshima bomb discovery shocks scientists May 1, 2018
  • Earth will be slammed by massive asteroid April 29, 2018
  • Teens are doing something incredibly alarming in schools April 29, 2018
  • Huge discovery in Tasmania stuns scientists April 28, 2018
  • Shocking discovery in New Jersey stuns authorities April 22, 2018
  • Huge volcanic explosion could wipe out the United States April 21, 2018
  • Huge controversy erupts over world’s hottest pepper April 15, 2018
  • SpaceX is about to do something astonishing April 15, 2018

Copyright © 2021 Jones Kilmartin Group, LLC · Metro Pro Theme On Genesis Framework · WordPress